Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Article
Novel Oral Anticoagulant Reversal Agent Tops AJPB Week in Review
Author(s):
Top news of the week from The American Journal of Pharmacy Benefits.
5. FDA OKs Treatment Combo for Advanced Renal Cell Carcinoma
Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma. Read more.
4. Congress, Medical Societies Address Approaches to Combat Opioid Crisis
Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week. Read more.
3. Artificial Pancreas Improves Blood Sugar Control in Type 1 Diabetes
An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study. Read more.
2. Childhood Factors May Contribute to COPD Risk
Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Read more.
1. FDA Approves First Novel Oral Anticoagulant Reversal Agent
The approval is the first of its kind for a reversal agent of a novel oral anticoagulant (NOAC). Read more.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
Published: July 10th 2025 | Updated: July 10th 2025
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk
